Popular Articles

Prometheus Announces New Findings Regarding Patients At Risk For Celiac Disease At DDW
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn"s disease and particular genetic markers in patients at risk for celiac disease. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a statistically significant correlation between antibodies to the flagellin CBir1 and HLA haplotypes DQ2.5 and DQ8 in a study of 5,406 patients at risk for celiac disease who are EMA positive. Blood and serum samples were analyzed using PROMETHEUS(R) Celiac PLUS and PROMETHEUS(R) IBD Serology 7 diagnostic tests.
generic viagra online
STAAR Surgical Receives FDA Clearance For The Epiphany(TM) Injector System
STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the FDA has granted 510(k) clearance for its Epiphany Injector System for use with the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone NTIOL. Introduction of the Epiphany will usher in a new era of insertion devices for the company and pave the way for the future introduction of a preloaded injector for the U.S. market.
News of the day
Fluidigm Introduces New TOPAZ(R) Protein Crystallization Chip That Provides A "Screen To Beam" Solution
In the rarified world of protein crystal hunters, Fluidigm"s TOPAZ® system is the tool that has helped researchers solve the structures of proteins from the Ebola Virus and Avian Flu Influenza. Now Fluidigm is introducing its new 1.96 Diffraction Capable (DC) integrated fluidic circuit which will allow researchers something they have long sought - direct screen-to-beam capabilities without the need to physically harvest a crystal from the device.
Endocrinology

Responding To Global Health Crises: Seminar, Australia

How The World Health Organization develops its policy recommendations and responds to global health crises is the subject of a talk at The Australian National University today. The seminar will be given by Dr Tikki Pang, Director of Research Policy and Cooperation at the World Health Organization (WHO). In addition to discussing his role at the WHO, Dr Pang will also talk about the role that primary health care plays in developing countries. Dr Pang, an ANU graduate, is also Secretary of the WHO Research Ethics Review Committee and Advisory Committee on Health Research. Prior to joining the WHO, he was Professor of Biomedical Sciences at the University of Malaya. Dr Pang is a Fellow of the Royal College of Pathologists (UK), Institute of Biology (UK), American Academy of Microbiology (USA), Academy of Medicine of Malaysia and Academy of Sciences for the Developing World (TWAS), and a Member of the International Molecular Biology Network (IMBN). He holds a PhD in Immunology-Microbiology from ANU. SEMINAR: Global perspectives on health policy development: from evidence to practice WHO: Dr Tikki Pang, World Health Organization, Director of Research Policy & Cooperation WHEN: 3pm - 4.30pm, Monday 13 July WHERE: Finkel Theatre, The John Curtin School of Medical Research, Garran Road, ANU. Australian National University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):